Clonal Hematopoiesis of Immunological Significance (CHIS)

Assistance Publique - Hôpitaux de Paris

Status: Not yet enrolling

Conditions: Inflammation; Myeloproliferative Disorders; Immune System Diseases; Leukemia; Monoclonal Gammopathy of Undetermined Significance; Myelodysplastic Syndromes; Autoimmune Diseases; Clonal Hematopoiesis of Indeterminate Potential; Leukemia Myelomonocytic Chronic; Hematopoiesis Clonal; Myelodysplastic-Myeloproliferative Diseases; Lymphoma; Autoinflammatory Diseases; Vexas Syndrome; Lymphoproliferative Disorders; Hematologic Diseases

Treatments: Other: observational cohort study

Study type: Observational

Funder types: Other

Identifiers

NCT05969821

APHP221121

Details and patient eligibility

About

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Full description

The clinical spectrum of dysimmune manifestations associated with blood diseases is wide. The pathophysiology of these manifestations is not well understood and their management is poorly codified. This observational cohort aims to list the different clinical pictures, the therapeutic management and the prognosis of patients according to the type of dysimmune manifestations and the type of hemopathy. We wish to have an inventory of the demographic, genetic, clinical and evolutionary data of patients with an inflammatory manifestation associated or not with a myeloid or lymphoid hemopathy. This will make it possible to establish quantitative data on the morbidity and mortality of these rare diseases and to propose therapeutic trials for the most serious patients.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >=18 years old
• Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease
• Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification

Exclusion criteria

• Persons benefiting from special protection: adults under guardianship and curatorship; people hospitalized without their consent and not protected by law; persons deprived of liberty.
• Persons not affiliated to the social security system

Trial design

1,000 participants in 1 patient group

Dysimmune manifestations with or without clonal hematopoiesis

Description:

Dysimmune manifestations with or without clonal hematopoiesis

Treatment:

Other: observational cohort study